HRAS and cancer: A recent study has demonstrated that oncogenes found in many cancer entities, such as MYC, aurora kinase B (AURKB) and HRAS, trigger hyperactivation of ESCRT and ceramide pathways, as well as the inhibition of lysosome genes causing abundant sEV secretion.